Scarica l'app Stockscreener
12.65
0.80%
0.10
Dopo l'orario di chiusura:
12.77
0.12
+0.95%
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
ZVRA Price Today: Zevra Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Zevra Therapeutics Q2 2025 Earnings Preview - MSN
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA Maintained by Canaccord Genuity -- Price Target Stays at $2 - GuruFocus
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $29 - Moomoo
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - The Manila Times
Press Release: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - Moomoo
ZVRA Upgraded by Guggenheim -- Price Target Raised to $29 - GuruFocus
ZVRA Maintains Rating by Maxim Group -- Price Target Raised to $35.00 - GuruFocus
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $34 - Moomoo
Zevra Therapeutics Is Maintained at Buy by Maxim Group - Moomoo
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Guggenheim raises Zevra Therapeutics price target on patent extension - Investing.com UK
Guggenheim raises Zevra Therapeutics price target on patent extension By Investing.com - Investing.com Nigeria
ZVRA Reiterates by BTIG -- Price Target Raised to $27.00 - GuruFocus
Liquidity Mapping Around (ZVRA) Price Events - Stock Traders Daily
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? - Yahoo Finance
BTIG raises Zevra Therapeutics price target to $27 on patent filing - Investing.com Nigeria
ZVRA Maintains Buy Rating -- Price Target Raised to $29.00 by Ca - GuruFocus
BTIG raises Zevra Therapeutics price target to $27 on patent filing By Investing.com - Investing.com India
ZVRA stock hits its highest levels in nearly 5 years – what’s driving this sharp rally today? - MSN
ZVRA Maintains by Citizens -- Price Target Raised to $25.00 - GuruFocus
Zevra Therapeutics stock price target raised to $29 by Canaccord on patent extension - Investing.com South Africa
H.C. Wainwright reiterates Zevra Therapeutics stock rating on patent extension - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity By Investing.com - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity - Investing.com
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
ZVRA Maintained by Cantor Fitzgerald -- Price Target Raised to $34 - GuruFocus
Zevra Therapeutics (ZVRA) Files New Patent for Miplyffa - GuruFocus
Why is Zevra Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Why is Zevra Therapeutics stock surging today? - Investing.com
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug - Yahoo Finance
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041 - Yahoo Finance
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA - The Manila Times
Zevra moves to list rare disease drug MIPLYFFA in FDA Orange Book - Stock Titan
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):